8. PIŚMIENNICTWO
1. Afanasev I. B.: Superoxide ion: chemistry and biological implications. CRC Press, Boca Raton, Fla, U.S.A. 1991, 152-167.
2. Alberts B., Bray D., Lewis J., Raff M., Roberts K., Watson J.D.: Molecular biology of the cell. Garland Publishing, New York, 1983.
3. Allen J., Cooper D. jr., Merrill W. M.: Modulation of endoperoxide product levels and cyclophosphamide-induced injury by glutathione repletion. J. Appl. Physiol. 1989, 67(6), 2316-2322.
4. Altman H.W.: Drug induced liver reactions: a morphplogical approach . Curr. Tpo. Pathol.,1980, 69, 69-142.
5. Ambrus J. L., Ambrus C. M., Taheri S. A., Gastpor H., Reddington M., Taheri P., Kahn E. A., Schattman G. L., Deon L. S., Moore R. H.: Red cell flexibility and platelet aggregation in patients with chronic obstructive vascular disease (COAD) and study of therapeutic approaches. Angiology 1984, 7, 418-426.
6. Angelkort B., Kisewetter H.: Influence of risk factors and coagulation on the fluidity of blood in chronic arterial occlusive disease. Scand. J. Clin. Lab. Invest., 1981, 41(suppl. 156), 185-188.
7. Angelkort B, Maurin N., Boateng K.: Influence of pentoxifylline on erytrocyte deformability in peripherial occlusive arterial disease. Curr. Med. Res. Opin., 1979, 6, 255-258.
8. Aubrey D.A.: Massive hepatic necrosis after cyclophosphamide.Brit. Med. J. 1970, 3, 58.
9. Aviado M., Dettelbach H.R.: Pharmacology of pentoxifylline a hemorheologic agent for the treatment of intermittent claudication. Angiology, 1984, July, 407-417.
10. Bachet P., Lancrenon S., Chassoux G.: Fibrynogen and pentoxifylline. Thrombosis Res., 1989, 55, 161.
11. Beck F., Lloyd J.B.: The cell in medical science. Vol. 1, chpt. 6 - Mitochondria and peroxysomes. Academic Press, London, New York, 1974.
12. Berrigan M.J., Gurtoo H.L., Sharma S.D., Struck R.F., Marinello A.J.: Protection by N-acetylcysteine of cyclophosphamide metabolism-related in vivo depression of mixed function oxygenase activity and in vitro denaturation of cytochrom P-450. Biochem. Biophys. Res. Commun., 1980, 93, 797-803.
13. Bessler H., Gigal R., Djaldetti M., Zahavi I.: Effect of pentoxifylline on phagocytic activity, cAMP levels and superoxide anion production by monocytes and polymorphonuclear cells. J. Leucocyte Biol., 1986, 40, 747-754.
14. Billingham M., Mason J.: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep., 1978, 62, 865.
15. Bogdanikowa B. (red.): Leczenie immunosupresyjne. PZWL, Warszawa, 1975
16. Boogaerts M.A., Malbrain S., Meens P., van Hove L., Verhoef G.E.: In vitro modulation of normal and diseased human neutrophil function by pentoxifylline. Blut., 1990, 61(2-3), 60-65.
17. Brock N.: Oxazaphosphorine cytostatics: past - present - future. Cancer Res., 1989, 49, 1-7.
18. Brock N., Hohorst H.J.: Metabolism of cyclophosphamide. Cancer, 1967, 20(5), 900-904.
19. Brock N., Hohorst H.J.: The problem of specificity and selectivity of alkylating cytostatics: studies on N-2-chloroethyloamido-oxazaphosphorines. Z. Krebsforsh, 1977, 88, 185-215.
20. Brzozowski R. (red.): Choroby wątroby i dróg żółciowych. PZWL, Warszawa, 1991.
21. Buchanan N., Moodly G.P.: The effect of pentoxifylline on human erythrocyte adenosine triphosphate. IRCS Med. Sci., 1977, 5, 43.
22. Cadman E.: Toxicity of chemotherapeutic agents. w Cancer - a comprehensive treative. Plenum Press, New York, 1977.
23. Chodorowski M.: Pentoksyfilina w leczeniu chorób naczyń obwodowych. Terapia i Leki, 1994, 12, 420-428.
24. Ciuffetti G., Mercuri M., Ott C., Lombardini R., Paltriccia R., Lupattelli G., Santambrogio L., Mannario E.: Use of pentoxifylline as an inhibitor of free radical generation in peripherial vascular disease. Eur. J. Clin. Pharmacol., 1991, 41, 511-515.
25. Cohen J.L., Jao J.Y.: Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J. Pharmacol. Experim. Treat., 1970, 174(2), 206-210.
26. Cooperating Clinics Committee of the American Rheumatism Association: A controlled trial of cyclophosphamide in rheumatoid arthritis. New Engl. J. Med., 1970, 283, 883-889.
27. Coster S.K.: Single and combination nonhormonal chemotherapy in brest cancer. Cancer (Phila.), 1972, 30, 1543-1555.
28. Czarnicki Z.: Zagadnienie ochrony personelu zatrudnionego przy pracy z cytostatykami. Pol. Tyg. Lek., 1987, 42(51-52), 1662-1663.
29. Dahl M., Gregory M.: Liver damage due to methotrexate in patients with psoriasis. Brit. Med. J., 1971, 1, 625.
30. Danysz A., Gryglewski R.: Farmakologia. PZWL, Warszawa, 1982
31. Davis M.: Drugs and hepatotoxicity w Liver (red. Williams R., Maddrey W.C.) Butterworths, Londyn 1984.
32. Deneke S.M., Fanburg B.L.: Regulation of cellular glutathion. Amer. J. Physiol., 1989, 257, 163-173.
33. Ehrly A.M.: The effect of pentoxifylline on the deformability of erythrocytes and on muscular oxygen pressure in patients with chronic arterial disease. J. Med., 1979, 10, 331.
34. Ellermann J., David H., Luning M., Gewiese B., Stiller D., Romer T., Plotz M, Wolf K.J.: Effects of pentoxifylline on the recovery of the preserved rat liver: 31P NMR and ultrastructural studies. NMR-Biomed., 1991, 4(6), 286-93.
35. Fiejka E.: Morfologiczna ocena wpływu skojarzonego stosowania cyklofosfamidu i aktynomycyny D na regenerujący miąższ wątroby. Pat. Pol., 1986, 37, 145-154.
36. Freeman B.A., Crapo J.D.: Free radicals and tissue injury. Lab. Invest., 1982, 47, 412-426.
37. Granger D.N., Hollwarth E., Parks D.A.: Ischemia - reperfusion injury: role of derived free radicals. Acta Physiol. Scand. (suppl.), 1986, 548, 47-63.
38. Green M.: Acute non-lymphocytic leukemia after therapy with alkylating agents for ovarian cancer, a study of five randomized clinical trials. New Engl. J. Med., 1982, 307, 1416.
39. Greene E.L., Paller E.S.: Oxygen free radicals in acute renal failure. Minuer Electrolyte, 1991, 17, 391-401.
40. Groniowski J., Kruś S.: Podstawy patomorfologii. PZWL, Warszawa, 1984
41. Guillot M., Marcel G.A., Stoltz F.F.: Influence of pentoxifylline on erythrocyte filterability and microrheology - a pharmacological study. 3rd Int. Congr. Biorheology, La Jolla, Ca., U.S.A., 1978.
42. Gurtoo H.L., Hipkens J.H., Sharma S.D.: Role of glutathione in the metabolism dependent toxicity and chemotherapy of cyclophosphamide. Cancer Res., 1981, 41, 3584-3591.
43. Harrison B.: Developing guidelines for working with antineoplastic drugs. Amer. J. Hosp. Pharmacol., 1981, 38,1686.
44. Hart L.G., Adamson R.H.: Effect of microsomal enzyme modifiers on toxicity and therapeutic activity of cyclophosphamide in mice. Arch. Int. Pharmacodyn., 1969, 180(2), 391-401.
45. Hersh E.: Antineoplastic and immunosupressive agents. Part I. Springer Verlag, New York, 1974.
46. Hess H., Franke I., Jauch M.: Improvement of the fluidity of the blood with medication. An effective principle for the treatment of disturbances of the arterial blood flow. Fortschr. Med., 1973, 91, 743-748.
47. Hewett J.A., Jean P.A., Kunkel S.L., Roth R.A.: Relationship between tumor necrosis factor-alpha and neutrophils in endoxin-induced liver injury. Am. J. Physiol., 1993, 256(6, pt 1), 1011-1015.
48. Hinkle P.C.: Mitochondria w The Liver: Biology and Pathobiology (red. Arias I. M and all.) Raven Press, New York 1982, 1-8.
49. Hinze H.J., Grigoleit H.G., Rethy B.: Bioavailability and pharmacokinetics of pentoxifylline from Trental 400 in man. Pharmatherapeutica, 1976, 1, 160-171
50. Holliwell B., Gutteridge J.: Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys., 1986, 246, 501-551.
51. Humphrey R.L., Krds L.K., Braine H.F., Aleloff M.D.: High dose therapy of poor-risk myeloma and Waldenstrom?s macroglobulinemia. Proc. Am. Assoc. Cancer Res., 1973, 14, 54.
52. Johannessen J.V.: Electron microscopy in human medicine. Vol. 2 - Cellular pathobiology. McGrow-Hill Int. Book Co, 1978.
53. Johannessen J.V.: Electron microscopy in human medicine. Vol. 8 - The Liver. The Gallbladder and biliary ducts. McGrow-Hill Int. Book Co., 1979.
54. Kawabata T.T., Chapman H.Y., Kim D.H., Stevens W.D., Holsapple M.P.: Mechanism of in vitro immunosupresion by hepatocyte-generated cyclophosphamide metabolites and 4-hydroperoxycyclophosphamide. Biochem. Pharmacol., 1990, 40(5): 927-935.
55. Khan S., Ramwani J.J., O?Brien P.J. - Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation.?, Biochem. Pharmacol., 1992, 43(9), 1963-1967.
56. Klanova H., Mozes J.: Clinical experiences with agapurin in peripheral angiopathies. Respharma, 1987, 12, 25-29.
57. Kruś S.: Anatomia patologiczna. PZWL, Warszawa, 1980.
58. Kruś S.: Patomorfologia wątroby. PZWL, Warszawa, 1986.
59. Lares R.M. jr., Penner J.A.: Refractory thrombocytopenic purpura treated successfully with cyclophosphamide. J. Am. Med. Assoc., 1971, 215, 445-449.
60. Lassila O., Toivanen A.: Immune function in nurse handling cytotoxic drugs. Lancet, 1984, 2, 482.
61. Lavin P., Koss L.G.: Effects of a single dose of cyclophosphamide on various organs in the rat. III. Electron microscopy study of the liver. Amer. J. Path., 1971, 62, 159-165.
62. Le J., Vilcek J.: Biology of disease. Tumor necrosis factor and interleukin-1: cytokines with multiple overlapping biological activities. Lab. Invest., 1987, 56, 234-247.
63. LeBlanc G.A., Waxman D.J.: Mechanism of cyclophosphamide action on hepatic P-450 expression. Cancer Res., 1990, 50(18), 5720-5726.
64. Lenhard R.E. jr., Prentice R.L., Owens A.H. jr., Bakemejer R., Horton J.H., Shnider B.I., Stolbock L., Berard C.W., Carbone P.P.: Combination chemotherapy of the malignant lymphomas. Cancer (Phila.), 1976, 38, 1052-1059.
65. Leonhardt H., Grigoleit H.G.: Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions. Naunyn Schmiedeberg Arch. Pharmacol., 1977, 294, 197-200.
66. Liczmarski A.E.: Toksyczność tlenu. I. Uszkodzenia żywych komórek. Post. Biochem., 1988, 34(4), 273-291.
67. Liebhart M., Koch I., Kaczkowska E.: Morfologiczna ocena jajnika i wątroby po zastosowaniu wielokrotnych terapeutycznych dawek cyklofosfamidu u niedojrzałych gryzoni doświadczalnych w różnych okresach rozwoju osobniczego. Prob. Med. Wieku Rozw., 1989, 16, 197-203.
68. Livingston R.B., Carter S.K.: Cyclophosphamide. w: Single agents in cancer chemotherapy. Plenum Publishing Corp., New York, 1970, 28.
69. Luna M., Bedrossian C.: Interstitial pneumonitis associated with bleomycin therapy. Amer. J. Clin. Pathol., 1972, 58, 501.
70. Madras N., Harrington J.: Platinum nephrotoxicity. Amer. J. Med., 1978, 65, 307.
71. Malec J.: Rola rodników tlenowych i antyoksydantów w ubocznej toksyczności chemioterapii przeciwnowotworowej oraz próby jej zapobiegania. Wiad. Lek., 1989, 42(19-21), 1044-1051.
72. Marinello A.J., Gurtoo H.L., Struck R.F., Paul B.: Denaturation of Cytochrome P-450 by cyclophosphamide metabolites. Biochem. Biophys. Res. Commun., 1978, 83(4), 1347-1353.
73. Marzella L., Glaumann H.:Effects of in vivo liver ischemia on microsomes and lysosomes. Virchows Arch., 1981, 36, 1-35.
74. Marsh J.: The effects of cancer chemotherapeutic agents on normal hematopoetic precursor cells - a review. Cancer Res., 1976, 36, 1853-1925.
75. Matsuda Y., Higashiyama S., Kijima Y., Suzuki K., Kawano K., Akiyama M., Kawata S., Tami S., Deutsch H.F., Taniguchi N.: Human liver manganese superoxide dismutase - purification and crystallization, subunit association and sulfhydryl reactivity. Eur. J. Biochem., 1990, 194, 713-720.
76. Matzky R., Darius R., Schroer K.: The release of prostacyclin (PG I2) by pentoxifylline from human vascular tissue. Artzneimettelforsch, 1982, 32, 1315-1318.
77. Miętkiewski K., Karoń H., Warchoł J.B., Król C.: Wpływ cyklofosfamidu (Endoksanu) na odczyny histochemiczne w wątrobie. I. Badania histoenzymatyczne. Pat. Pol., 1973, 24(1), 145-155.
78. Mordarski M.: Cytostatyki. I. Związki alkilujące. Post. Hig. Med. Dośw., 1970, 24, 609-638.
79. Mueller R.: Hemorheology and peripherial vascular disease: a new therapeutic approach. J. Med., 1981, 12, 209-236.
80. Mueller R.: Pentoxifylline - a biomedical profile. J. Med., 1979, 10, 307.
81. Nicholson H.: Cytotoxic drugs in pregnancy. Review of reported cases. J. Obst. Gyn. Brit. Comm., 1968, 75, 307.
82. Oliver C.N.: Inactivation of enzymes and oxidative modification of proteins by stimulated neutrophils. Arch. Biochem. Biophys., 1987, 253, 63-72
83. Ostrowski K. (red.): Histologia. PZWL, Warszawa, 1988
84. Pawelski S., Maj S.: Normy i kliniczna interpretacja badań diagnostycznych w medycynie wewnętrznej. PZWL, Warszawa, 1981.
85. Perego M.A., Sergio G., Artale F.: Hemorheological aspect of the pathophysiology and clinical features of peripherial occlusive arterial disease. Pharmatherapeutica, 1983, 3(suppl. 1), 91-101.
86. Phillips M.J., Poucell S., Patherson J., Valencia P.: The Liver. An Atlas and text of ultrastructural pathology. Raven Press Book Ltd, New York, 1987.
87. Podlewski J.K., Podlewska-Chwalibogowska A.: Leki współczesnej terapii. PZWL, Warszawa, 1985.
88. Porsche E., Stefanovich V., Grigoleit H.G.: Inhibition of K+ leakage from human red blood cells by pentoxifylline. IRCS Med. Sci., 1977, 5, 484.
89. Pryor W.A.: Free radicals in autooxidation and in aging. w: Free radicals in molecular biology. Aging and disease. Armstrong D., Raven Press, New York, 1984, 13.
90. Ross L., Barcklay C., Vinqvist M.R.: Membrane peroxidation inhibiting effects of water soluble antioxidants on phospholipides of different charge types. Free Radical Biol. Med., 1994, 16, 779 -788.
91. Rothman J.E.: The compartmental organization of the Golgi apparatus. Sci. Am., 1985, 253, 74-89.
92. Ruffolo R., Covington H.: Matrix inclusion bodies in the mitochondria of the human liver. Evidence of hepatocellular injury. Amer. J. Pathol., 1967, 51(1), 101-116.
93. Santos G.W., Sensenbrenner L.L., Anderson P.N., Burke P.J., Klein D.L., Slavin R.E., Schackter B., Borgaonkar D.S.: HL-A-identical marrow transplants in aplastic anemia, acute leukemia and lymphosarcoma employing cyclophosphamide. Transplant. Proc., 1976, 8, 607-610.
94. Schubotz R., Muehfellner O.: The effect of pentoxifylline on erythrocyte deformability and on phosphatide fatty acid distribution in the erythrocyte membrane. Curr. Med. Res. Opin., 1977, 4, 609-617.
95. Schulsky R., Levis B.: Gonadal disfunction in patients receiving chemotherapy for cancer. Amer. Intern. Med., 1980, 99, 109 .
96. Seiffge D.: Effect of pentoxifylline on red cell aggegation. IRCS Med. Sci., 1982, 8, 727.
97. Seiffge D., Kiesewetter H. - ?Effect of pentoxifylline on single red cell deformability.?, Klin. Wichr., 1981, 59: 1271-1272.
98. Shibayama Y., Asaka S., Nakata K. - ?Role of activated macrophages in augmentation of endotoxin hepatotoxicity.?, Exp. Toxicol. Pathol., 1994, 45(8): 497-502.
99. Sigurdsson G.H., Youssef H.: Effects of pentoxifylline on hemodynamics, gas exchange and multiple organ platelet sequestration in experimental endotoxic shock. Acta Anaesthesiol. Scand., 1993, 37(4), 396-403.
100. Sikora E.: Udział aktywnych form tlenu w różnicowaniu, promocji nowotworu i starzeniu. Post. Biochem., 1989, 35(4), 563-574.
101. Sladek N.E.: Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res. , 1971, 31, 901-908.
102. Smud R., Sermukslis B., Kortin D.: Changes in blood viscosity induced by pentoxifylline. Pharmatherapeutica, 1976, 1, 229-233.
103. Snyder L.S., Heigh R.I., Anderson M.L.: Cyclophosphamide induced hepatotoxicity in patient with Wegener?s granulomatosis. Mayo Clinic Proc., 1993, 68, 1203-1204.
104. Spotsman H.: Cytotoxic drugs induced lung disease. Amer. J. Med., 1977, 62, 608.
105. Stachura J., Papla B., Dubiej-Bigaj M.: The influence of cyclophosphamide on some hydrolases and oxidising enzymes in the livers and kidneys of mice. Acta Med. Pol., 1968, 9, 319.
106. Stefanovich V.: Effect of pentoxifylline on energy rich phosphates in rat?s erythrocytes. Res. Commun. Chem. Pathol. Pharmacol., 1975, 10, 747-750
107. Stenger R.J.: Organelle pathology of the liver: the endoplasmic reticulum. Gastroenterology, 1970, 58, 554.
108. Wagoner L.E., Olsen S.L., Bristow M.R., O?Connell J.B., Taylor D.O., Lappe D.L., Renlund D.G.: Cyclophosphamide as an alternative to azathioprine in cardiac transplant recipients with suspected azathioprine-induced hepatotoxicity. Transpl., 1993, 56(6), 1415-1418.
109. Walling C. w: Oxidases and related redox systems. (red. King T.E., Mason H.S., Morrison H.S.), Pergamon Press, Oxford, 1982, 85-97.
110. Wang P., Ba Z.F., Morrison M.H., Ayala A., Chaudry I.H.: Mechanism of the beneficial effects of pentoxifylline on hepatocellular function after trauma hemmorhage and resuscitation. Surgery, 1992, 112(2), 451-7.
111. Ward A., Cissold S.: Pentoxifylline. A review of its pharmacodynamic and pharmacokinetc properties, and its therapeutic efficacy. Drugs, 1987, 34, 50.
112. Weiss H.: Neurotoxicity of commonly used antineoplastic agents. New England J. Med., 1975, 75, 127.
113. Weithmann K.U.: Reduced platelet aggregation by pentoxifylline stimulated prostacyclin release. VASA, 1981, 10, 249-252.
114. Welty S.E., Smith C.V., Benzick A.E., Montgomery C.A., Hansen T.N.: Investigation on possible mechanisms of hepatic swelling and necrosis caused by acetaminophen in mice. Biochem. Pharmacol., 1993, 45(2), 449-458.
115. Youn Y.K., Knox J., Lalonde C., Demling R.: Pentoxifylline does not prevent endotoxin induced lung and liver lipid peroxidation in adoult sheep. Circ-Shock, 1993, 39(1), 39-43.
116. Zinke H., Woods J.E.: Donor pretreatment in cadaver renal transplantation. Surgery Gyn. Obstet., 1977, 145, 183-188.